# Capecchi Gene Targeting and the Knockout Mouse

**Type:** work
**Status:** Draft
**Confidence:** Medium
**Focus:** gene targeting, knockout mice, biomedical research, genetics
**Era:** 1973-present; core breakthrough in the 1980s; Nobel Prize in 2007
**Location:** University of Utah, Salt Lake City, UT
**Updated:** 2026-05-16
**Pull:** *A Utah lab helped make it possible to ask what any mammalian gene does by removing it on purpose.*

## Summary

Mario Capecchi joined the University of Utah in 1973 and spent decades developing gene targeting: a method for modifying a specific gene in a living mouse by using homologous recombination and selection strategies to find the rare cells where the intended edit occurred. Combined with embryonic stem-cell methods developed by Martin Evans and related work by Oliver Smithies, the technique made the knockout mouse practical.

Capecchi shared the 2007 Nobel Prize in Physiology or Medicine with Evans and Smithies for discoveries involving embryonic stem cells and DNA recombination in mammals. For the wiki, the Utah claim is not that the whole method was invented by one person in one place. The claim is narrower and stronger: Capecchi's Utah lab made targeted mammalian gene modification practical enough to become one of the central tools of modern biomedical research.

## Why It Matters

Knockout mice changed how biologists asked causal questions. Instead of waiting for natural mutations or using random mutagenesis, researchers could disable a chosen gene and observe development, physiology, disease, and drug response in a whole organism. Cancer, neurodegeneration, cardiovascular disease, immunology, metabolic disease, and developmental biology all absorbed the tool.

The intellectual move also anticipates later genome editing. CRISPR uses different molecular machinery and is often faster, but the basic experimental logic is familiar: choose a genomic target, alter it deliberately, and use the resulting organism or cell to learn function.

## What Was Built

The hard technical problem was rarity. Homologous recombination in mammalian cells happens infrequently, and random DNA integration is much easier than a precise replacement at the intended locus. Capecchi's positive-negative selection strategy helped separate correctly targeted cells from the much larger background of incorrect integrations.

The work also required a full pipeline: engineered constructs, embryonic stem cells, selection, chimeric mice, breeding, and phenotyping. The outcome was not a single device or product but a reusable research method.

## Utah Context

The University of Utah gave Capecchi a long research home, and the story remains one of the strongest examples of basic biology in Utah changing global medicine indirectly. It connects to Utah's later life-sciences ecosystem, but its main importance is scientific: it made Utah part of the everyday experimental toolkit of molecular biology and drug discovery.

## Caveats

The Nobel was shared for good reason. Evans's embryonic stem-cell work and Smithies's independent homologous-recombination work were essential. Knockout mice are also slow and expensive, and CRISPR has displaced some older workflows. The lasting claim is not that the original technique remains the fastest tool, but that it opened the precision mammalian genetics era.

## Evidence

- [Official Source: Nobel Prize Capecchi Gene Targeting](nobel-prize-capecchi-gene-targeting.md)
- [University of Utah Health: Mario Capecchi profile](https://healthcare.utah.edu/capecchi)
- [The first transgenic mice: interview with Mario Capecchi](https://pmc.ncbi.nlm.nih.gov/articles/PMC2590805/)
- [Learn.Genetics: transgenic mice](https://learn.genetics.utah.edu/content/science/transgenic/)

## Open Questions

- Add a source record for the Nobel announcement and a tighter citation for the positive-negative selection mechanism.
- Consider whether this should cross-link to a future `people/mario-capecchi.md` page if the wiki starts adding real researcher biographies.